All In Biotech

Drug Trial Radar · NCT07700875

A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled, Parallel-Group Study of the Efficacy and Safety of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension

Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 391 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

391

Actual

Start

Dec 29, 2022

Primary completion

Aug 20, 2023

Study completion Sep 11, 2023

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.

Conditions

  • Essential Hypertension

Interventions

  • QR12000 Compound Tablets 75 mgDrug

    QR12000 Compound Tablets 75 mg QD

  • QR12000 Compound Tablets 75 mg placeboDrug

    Matching placebo of QR12000 Compound Tablets 75 mg QD

  • QR12000 Compound Tablets 150 mgDrug

    QR12000 Compound Tablets 150 mg QD

  • QR12000 Compound Tablets 150 mg placeboDrug

    Matching placebo of QR12000 Compound Tablets 150 mg QD

  • QR01019 potassium salt 50 mgDrug

    QR01019 potassium salt 50 mg QD

  • QR01019 potassium salt 50 mg placeboDrug

    Matching placebo of QR01019 potassium salt 50 mg QD

  • Sacubitril / valsartan 200 mgDrug

    Sacubitril / valsartan 200 mg QD

  • Sacubitril / valsartan 200 mg placeboDrug

    Matching placebo of Sacubitril / valsartan 200 mg QD

  • Valsartan 160 mgDrug

    Valsartan 160 mg QD

  • Valsartan 160 mg placeboDrug

    Matching placebo of Valsartan 160mg QD

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8Time frame: Baseline and week 8.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Qilu Hospital of Shandong University

    Jinan, Shangdong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.